Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Digitalis-ähnliche Eigenschaften des Prednison- und Prednisolonbisguanylhydrazons (1964)
    Springer
    Naunyn-Schmiedeberg's archives of pharmacology 249 (1964), S. 416-424 
    Details
    ISSN: 1432-1912
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary In isolated perfused guinea-pig hearts the positive inotropic effect of Prednison- and Prednisolon-bisguanylhydrazon is similar to k-Strophanthin connected with a loss of potassium. With increasing amounts there is in the non-toxic range a significant correlation of the magnitude of the inotropic effect and the amount of liberated potassium, whereas in the toxic range there is a strong increase of potassium loss. Prednisolonbisguanylhydrazon is 3–4 times more effective than k-Strophanthin and Prednisonbisguanylhydrazon. In cold stored erythrocytes Prednison and Prednisolonbisguanyl-hydrazon inhibit the active Na/K-transport of the rewarmed erythrocytes. There was a significant difference in effectiveness of the erythrocytes of men and guinea-pigs. An inhibition of 50% resulted from Prednisolon-, Prednisonbisguanylhydrazon or k-Strophanthin in erythrocytes of guinea-pigs in concentrations of 1,4, 17,4 and 4,1 μM/l respectively and in erythrocytes of man in concentrations of 63, 190 and 0,053 μM/l respectively.
    Notes: Zusammenfassung Am isoliert durchströmten Meerschweinchenherzen ist die positiv inotrope Wirkung des Prednison- und Prednisolonbisguanylhydrazons wie die des k-Strophanthins mit einer Kaliumabgabe verbunden. Mit ansteigender Dosierung besteht im nichttoxischen Dosierungsbereich eine deutliche Korrelation zwischen der Größe des inotropen Effektes und dem Ausmaß des Kaliumverlustes, während im toxischen Dosierungsbereich (Tachykardie, Arrhythmie oder Kontraktur) ein steiler Anstieg des Kaliumverlustes erfolgt. Prednisolonbisguanylhydrazon ist drei- bis viermal wirksamer als k-Strophanthin und Prednisonbisguanylhydrazon. An „Kälteerythrocyten“ hemmen Prednison- und Prednisolonbisguanylhydrazon den nach Erwärmen stattfindenden aktiven Na/K-Transport. Dabei bestehen an Erythrocyten des Menschen und Meerschweinchens deutliche Wirksamkeitsunterschiede: Eine 50%ige Hemmung erfolgte durch Prednisolon-, Prednisonbisguanylhydrazon bzw. k-Strophanthin an Meerschweinchenerythrocyten bei Konzentrationen von 1,4, 17,4 bzw. 4,1 μM/l und an Erythrocyten des Menschen bei 63, 190 bzw. 0,053 μM/l.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00247047
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Zum Wirkungsmechanismus der neuen herzwirksamen Sterinderivate Prednison- und Prednisolon-bisguanylhydrazon (1964)
    Springer
    Naunyn-Schmiedeberg's archives of pharmacology 247 (1964), S. 341-342 
    Details
    ISSN: 1432-1912
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02308437
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued (1992)
    Springer
    European journal of clinical pharmacology 43 (1992), S. 357-363 
    Details
    ISSN: 1432-1041
    Keywords: Parkinson's disease ; Bromocriptine ; L-Dopa/benserazide ; early combination therapy ; long-term ; therapy ; mortality ; cardioprotection
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary L-Dopa supplemented by a peripheral decarboxylase inhibitor is considered the most potent therapeutic regimen prolonging active life in Parkinsonian patients. The long-term benefit of therapy is limited by adverse effects, such as dyskinesia and on-off phenomena, which can be mitigated by the concomitant administration of dopamine agonists, such as bromocriptine. In order to quantify the beneficial impact of early combination therapy, a controlled clinical trial (PRADO:PRA vi-del1 +DOpa) in patients with early Parkinson's disease was carried out, whereby L-Dopa monotherapy (in a fixed combination with benserazide (DoBe) was being compared with the same combination plus bromocriptine (DoBeBro). Patients were recruited and treated by 101 practising neurologists in the Federal Republic of Germany and in Hungary. 'Twenty seven clinical university centers cross-checked the patients at regular intervals. The trial started with 3 months of DoBe monotherapy (median dose of 375 mg L-Dopa for both randomized groups) followed by gradual substitution of DoBe by bromocriptine over 3 months in one of the groups (250 mg L-Dopa/10 mg bromocriptine). The target medication was maintained from study months 6 to 54. Parkinsonian symptoms were classified according to the Webster rating scale, the Hoehn and Yahr scale and the Zung Self-Rating Depression Scale. Adverse events and life status were checked at regular intervals. Special emphasis was given to motor performance tests. 587 patients (302 in the DoBe group and 285 in the DoBeBro group) were available for intention-to-treat analysis. Both groups were homogeneous at baseline in all observed parameters. DoBe and DoBeBro proved equi-effective in terms of antiparkinsonian activity after the substitution phase (P II) had been completed. In September 1991, after a median observation period on target medication of 38.4 months in the DoBe group and 40.1 months in the DoBeBro group, 18 versus 8 deaths had been registered. The Logrank test as well as analysis using the Cox model, both adjusted for age and sex, showedP-values of 0.018 and 0.021, respectively. The mortality risk associated with L-Dopa therapy was reduced by more than 50 % by its combination with bromocriptine. The study was terminated due to this difference in mortality. The causes of death were classified by the treating physicians and consultants. At the time of study termination 152 patients in the DoBe group and 121 in the DoBeBro group had already discontinued study medication. Of those further 26 patients had died by the date of the final evaluation, 15 on DoBe and 11 on DoBeBro. The results imply that combination therapy with bromocriptine should be preferred over L-Dopa monotherapy from the very beginning.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02220609
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...